MA57399B1 - Inhibition de l'intégrine humaine alpha4beta7 - Google Patents

Inhibition de l'intégrine humaine alpha4beta7

Info

Publication number
MA57399B1
MA57399B1 MA57399A MA57399A MA57399B1 MA 57399 B1 MA57399 B1 MA 57399B1 MA 57399 A MA57399 A MA 57399A MA 57399 A MA57399 A MA 57399A MA 57399 B1 MA57399 B1 MA 57399B1
Authority
MA
Morocco
Prior art keywords
integrin
inhibition
human
diseases
treat
Prior art date
Application number
MA57399A
Other languages
English (en)
Inventor
Bruce N. Rogers
Robert Zahler
Fu-Yang Lin
Cheng Zhong
Eugene Hickey
Tyler DAY
Byungchan Kim
Matthew G. Bursavich
Dan CUI
James E. Dowling
Kristopher N. Hahn
Bryce A. Harrison
Blaise S. LIPPA
Dawn M. Troast
Kyle D. Konze
Aleksey I. Gerasyuto
Salma RAFI
Evelyne HOUANG
Original Assignee
Morphic Therapeutic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic, Inc. filed Critical Morphic Therapeutic, Inc.
Publication of MA57399B1 publication Critical patent/MA57399B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des petites molécules antagonistes de l'intégrine α4β7 et des procédés d'utilisation de celles-ci pour traiter un certain nombre de maladies et de pathologies.
MA57399A 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7 MA57399B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
PCT/US2020/055986 WO2021076890A1 (fr) 2019-10-16 2020-10-16 INHIBITION DE L'INTÉGRINE HUMAINE α4β7
EP20875989.4A EP4045039B1 (fr) 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7

Publications (1)

Publication Number Publication Date
MA57399B1 true MA57399B1 (fr) 2025-06-30

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57399A MA57399B1 (fr) 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7

Country Status (37)

Country Link
US (3) US11104661B1 (fr)
EP (3) EP4045039B1 (fr)
JP (7) JP7437490B2 (fr)
KR (2) KR20220102669A (fr)
CN (3) CN115087444B (fr)
AR (1) AR120244A1 (fr)
AU (2) AU2020366435A1 (fr)
BR (1) BR112022007284A2 (fr)
CA (1) CA3154269A1 (fr)
CL (1) CL2022000959A1 (fr)
CO (1) CO2022005759A2 (fr)
CR (1) CR20220205A (fr)
CU (1) CU20220027A7 (fr)
DK (1) DK4045039T3 (fr)
DO (2) DOP2022000081A (fr)
EC (1) ECSP22038978A (fr)
ES (1) ES3035561T3 (fr)
FI (1) FI4045039T3 (fr)
HR (1) HRP20250749T1 (fr)
HU (1) HUE071814T2 (fr)
IL (2) IL319053A (fr)
LT (1) LT4045039T (fr)
MA (1) MA57399B1 (fr)
MD (1) MD4045039T2 (fr)
MX (1) MX2022004406A (fr)
PE (1) PE20221829A1 (fr)
PH (1) PH12022550886A1 (fr)
PL (1) PL4045039T3 (fr)
PT (1) PT4045039T (fr)
PY (1) PY2065718A (fr)
RS (1) RS66976B1 (fr)
SI (1) SI4045039T1 (fr)
TW (7) TWI857592B (fr)
UA (1) UA130059C2 (fr)
UY (1) UY38926A (fr)
WO (3) WO2021076890A1 (fr)
ZA (2) ZA202203872B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
EP4541422A3 (fr) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
AU2020276277B2 (en) 2019-05-15 2025-03-20 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
WO2021076890A1 (fr) * 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE HUMAINE α4β7
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN118591535A (zh) * 2021-12-27 2024-09-03 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
JP2025530250A (ja) 2022-09-09 2025-09-11 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド プロピオン酸誘導体及びその医薬的な応用
KR20250120367A (ko) 2022-12-22 2025-08-08 신테라, 인크. 알파4 베타7 인테그린 안타고니스트 및 이의 용도
JP2026506997A (ja) * 2023-02-21 2026-02-27 シーフォーエックス・ディスカバリー・リミテッド 大環状アルファ４ベータ７インテグリン阻害剤
IL324720A (en) 2023-05-26 2026-01-01 Adarx Pharmaceuticals Inc SOD1 modulators and methods of using them
CN121712771A (zh) 2023-07-28 2026-03-20 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用
WO2025026955A1 (fr) * 2023-07-28 2025-02-06 Galapagos Nv Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
WO2025176107A1 (fr) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 Dérivés de pyridone et leur utilisation médicale
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (fr) * 2024-07-19 2026-01-22 C4X Discovery Limited Composés thérapeutiques
WO2026018017A1 (fr) * 2024-07-19 2026-01-22 C4X Discovery Limited Composés thérapeutiques
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159450C (fr) 1993-03-31 2002-01-08 Norman Anthony Abood 1-amidinophenyl-pyrrolidones piperidinones azetinones, inhibiteurs de l'agregation plaquettaire
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EP0932615A1 (fr) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
WO1998016524A1 (fr) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2333647A1 (fr) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) * 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
CA2385882C (fr) 1999-09-24 2009-11-24 Genentech, Inc. Derives de tyrosine
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
AU2001288515A1 (en) * 2000-08-30 2002-03-13 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (fr) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. Derive de morphinane substitue en position 7 par un carbamoyle et insature en positions 6 et 7
AU2006254772B2 (en) 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
EP3412309A1 (fr) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Procédés d'administration d'antagonistes de l'intégrine bêta7
EP2903691B1 (fr) 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Méthodes de diagnostic et de traitement de maladie intestinale inflammatoire
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
WO2016011940A1 (fr) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 Dérivé d'indole-amide, son procédé de préparation et son application en médecine
WO2016086147A1 (fr) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
KR20170120601A (ko) 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
MA47697A (fr) * 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
JP7365358B2 (ja) * 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
EP4541422A3 (fr) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
AU2019373242B2 (en) * 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
WO2021076890A1 (fr) * 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE HUMAINE α4β7

Also Published As

Publication number Publication date
JP7209116B2 (ja) 2023-01-19
IL292296A (en) 2022-06-01
JP7437495B2 (ja) 2024-02-22
ECSP22038978A (es) 2022-06-30
MX2022004406A (es) 2022-08-25
TWI775182B (zh) 2022-08-21
TW202126624A (zh) 2021-07-16
JP2022542184A (ja) 2022-09-29
DOP2022000081A (es) 2022-07-31
SI4045039T1 (sl) 2025-07-31
EP4559525A2 (fr) 2025-05-28
CN115087444A (zh) 2022-09-20
WO2021076890A1 (fr) 2021-04-22
EP4045039A1 (fr) 2022-08-24
CN115087444B (zh) 2024-09-17
JP2023036958A (ja) 2023-03-14
PT4045039T (pt) 2025-07-02
JP2024054293A (ja) 2024-04-16
JP2024116230A (ja) 2024-08-27
IL292296B1 (en) 2025-03-01
CU20220027A7 (es) 2022-12-12
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
DOP2025000034A (es) 2025-04-08
PL4045039T3 (pl) 2025-09-15
TWI802477B (zh) 2023-05-11
CN119192137A (zh) 2024-12-27
AU2020366435A1 (en) 2022-04-21
JP7500785B2 (ja) 2024-06-17
CN116783161A (zh) 2023-09-19
TW202315868A (zh) 2023-04-16
TWI840047B (zh) 2024-04-21
IL292296B2 (en) 2025-07-01
LT4045039T (lt) 2025-08-11
KR20220102669A (ko) 2022-07-20
MD4045039T2 (ro) 2025-11-30
TW202332675A (zh) 2023-08-16
PY2065718A (es) 2023-01-17
US11370773B1 (en) 2022-06-28
WO2022081983A1 (fr) 2022-04-21
JP2023500437A (ja) 2023-01-06
EP4228634A1 (fr) 2023-08-23
ZA202203872B (en) 2024-01-31
DK4045039T3 (da) 2025-06-30
AU2021361031A1 (en) 2023-06-08
CR20220205A (es) 2022-07-22
FI4045039T3 (fi) 2025-06-20
CL2022000959A1 (es) 2023-04-28
JP7702004B2 (ja) 2025-07-02
EP4045039A4 (fr) 2023-12-13
JP7437490B2 (ja) 2024-02-22
UA130059C2 (uk) 2025-10-29
UY38926A (es) 2021-05-31
TWI888065B (zh) 2025-06-21
US20240174632A1 (en) 2024-05-30
US11104661B1 (en) 2021-08-31
RS66976B1 (sr) 2025-07-31
KR20230088376A (ko) 2023-06-19
JP2024054296A (ja) 2024-04-16
TW202500559A (zh) 2025-01-01
HRP20250749T1 (hr) 2025-08-15
ES3035561T3 (en) 2025-09-04
PE20221829A1 (es) 2022-11-29
TWI900200B (zh) 2025-10-01
EP4559525A3 (fr) 2025-08-20
JP2022548809A (ja) 2022-11-22
CN116783161B (zh) 2026-04-03
JP7717202B2 (ja) 2025-08-01
PH12022550886A1 (en) 2023-05-03
CO2022005759A2 (es) 2022-05-20
WO2021076890A4 (fr) 2021-06-10
HUE071814T2 (hu) 2025-09-28
EP4045039B1 (fr) 2025-04-23
TWI791304B (zh) 2023-02-01
AR120244A1 (es) 2022-02-09
CA3154269A1 (fr) 2021-04-22
WO2021076902A1 (fr) 2021-04-22
EP4228634A4 (fr) 2024-12-18
TW202244040A (zh) 2022-11-16
BR112022007284A2 (pt) 2022-07-05
ZA202303992B (en) 2024-06-26
TW202500558A (zh) 2025-01-01
IL319053A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
MA57399B1 (fr) Inhibition de l'intégrine humaine alpha4beta7
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3735978A4 (fr) Composition pour améliorer, prévenir ou traiter des maladies de la peau comprenant une cellule souche mésenchymateuse dérivée d'une cellule souche pluripotente induite et un exosome dérivé de celle-ci
EP3856173A4 (fr) Traitement d'hémopathie maligne avec des inhibiteurs de ménine
MX2022009056A (es) Inhibidores de integrina ?v?6.
EP4067377A4 (fr) Développement et utilisation d'agents thérapeutiques pour des maladies associées à tslp
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
EP3937932A4 (fr) Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3955939A4 (fr) Méthodes et compositions utilisant des vésicules extracellulaires pour la détection de maladies et de troubles
EP3969009C0 (fr) Beta-1,3'-galactosyllactose destiné au traitement des troubles de la barrière intestinale
DE602007007618D1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
EP3911153A4 (fr) Traitement de maladies impliquant une déficience d'enpp1 ou d'enpp3
EP4073060A4 (fr) Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires